文献速递心血管CT

钙密度作为一级预防中冠状动脉斑块稳定标志物:CAUGHT-CAD试验

Calcium Density as a Marker of Coronary Plaque Stabilization in Primary Prevention: The CAUGHT-CAD Trial.
PubMed 文献 · JACC Cardiovasc Imaging · 2026-10-15

CAUGHT-CAD试验事后分析纳入338例无症状、未用他汀的中危个体,随机接受他汀为主的一级预防策略或常规护理,基线和3年行冠状动脉CTA。他汀治疗与中密度和高密度钙体积进展相关,同时非钙化斑块消退;LDL-C降低≥30%者高密度和极高密度钙进展更明显,提示钙密度增加可作为斑块稳定的标志。

要点

  • 冠脉CTA系列随访中,他汀治疗者钙化斑块向高密度shift,非钙化斑块消退,提示斑块稳定。
  • LDL-C降低≥30%与高密度和极高密度钙进展更明显相关,强化降脂可能促进斑块钙化成熟。
  • 阅片时可关注钙化斑块的密度构成变化,而不仅总钙化积分,辅助评估一级预防疗效。

关键影像表现/征象

  • 按HU将斑块分为非钙化(≤350 HU)、低密度钙(351-500 HU)、中密度钙(501-700 HU)、高密度钙(701-1000 HU)和极高密度钙(>1000 HU)五种亚型。
  • 他汀治疗与中密度钙(β=0.89,SE=0.39;P=0.02)和高密度钙(β=0.79,SE=0.24;P=0.001)体积进展相关,并伴非钙化斑块消退(β=-9.83,SE=1.64;P<0.001)。
  • 他汀治疗者中LDL-C降低≥30%与高密度钙(β=1.11,SE=0.49;P=0.03)和极高密度钙(β=1.68,SE=0.85;P=0.04)更大进展相关。

诊断标准与关键数值

  • 斑块亚型按HU阈值划分:非钙化≤350 HU,低密度钙351-500 HU,中密度钙501-700 HU,高密度钙701-1000 HU,极高密度钙>1000 HU。
  • 主要结局为按病变水平计算的钙化斑块亚型体积变化。

临床应用与阅片要点

  • 系列冠脉CTA随访中,他汀治疗者出现非钙化斑块消退伴钙化密度增高,可解读为斑块稳定化表现。
  • 报告时可描述钙化斑块的密度构成变化,结合LDL-C降幅评估一级预防疗效。

局限性

  • 本研究为CAUGHT-CAD试验的事后分析。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

BACKGROUND: Despite primary prevention statin treatment, a substantial proportion of individuals remain at residual risk for cardiovascular events. Coronary computed tomographic angiography (CTA) enables the quantification of compositional changes in calcified plaque.

OBJECTIVES: The aim of this study was to examine whether increases in coronary calcified plaque volume and density associated with statin therapy could be used as a marker of plaque stabilization in asymptomatic individuals undergoing serial coronary CTA.

METHODS: In the CAUGHT-CAD trial, asymptomatic, statin-naive, intermediate-risk individuals were randomized to a primary prevention strategy (including statin treatment) vs usual care. Participants underwent coronary CTA at baseline and 3 years. In this post hoc analysis, volumes of 5 plaque subtypes were quantified: noncalcified (≤350 HU), low-density calcium (351-500 HU), intermediate-density calcium (501-700 HU), high-density calcium (701-1000 HU), and very high density calcium (>1,000 HU). The primary outcome was the per-lesion level change in volumes of calcified plaque subtypes.

RESULTS: Eight hundred forty lesions were included from 338 participants (mean age: 58.3 ± 6.9 years, 57.1% men, 161 [47.6%] statin treated). Statin treatment was associated with greater progression in intermediate-density (β = 0.89, SE = 0.39; P = 0.02) and high-density (β = 0.79, SE = 0.24; P = 0.001) calcium, alongside regression of noncalcified plaque (β = -9.83, SE = 1.64; P < 0.001), following adjustment for cardiovascular risk factors, low-density lipoprotein cholesterol (LDL-C) level, and baseline plaque volume. Among statin-treated participants, LDL-C reduction ≥30% was associated with greater progression of high-density (β = 1.11, SE = 0.49; P = 0.03) and very high density (β = 1.68, SE = 0.85; P = 0.04) calcium.

CONCLUSIONS: In asymptomatic, intermediate-risk individuals, statin treatment was associated with a shift toward higher density calcium within coronary plaques, most marked with effective lowering of LDL-C. (Coronary Artery Calcium Score: Use to Guide Management of Hereditary Coronary Artery Disease [CAUGHT-CAD]; ACTRN12614001294640).

来源:JACC Cardiovasc Imaging,查看原文。版权归原作者所有。

引用

  1. Vasanthakumar SA, Nicholls SJ, Nerlekar N, et al. Calcium Density as a Marker of Coronary Plaque Stabilization in Primary Prevention: The CAUGHT-CAD Trial. JACC Cardiovasc Imaging. 2026. PMID: 42886154. doi:10.1016/j.jcmg.2026.07.029

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。